| Literature DB >> 34064356 |
Tabea Thies1,2, Doris Mücke2, Richard Dano3, Michael T Barbe1.
Abstract
The present study investigates speech changes in Parkinson's disease on the acoustic and articulatory level with respect to prosodic prominence marking. To display movements of the underlying articulators, speech data from 16 patients with Parkinson's disease were recorded using electromagnetic articulography. Speech tasks focused on strategies of prominence marking. Patients' ability to encode prominence in the laryngeal and supra-laryngeal domain is tested in two conditions to examine the influence of motor performance on speech production further: without dopaminergic medication and with dopaminergic medication. The data reveal that patients with Parkinson's disease are able to highlight important information in both conditions. They maintain prominence relations across- and within-accentuation by adjusting prosodic markers, such as vowel duration and pitch modulation, while the acoustic vowel space remains the same. For differentiating across-accentuation, not only intensity but also all temporal and spatial parameters related to the articulatory tongue body movements during the production of vowels are modulated to signal prominence. In response to the levodopa intake, gross motor performance improved significantly by 42%. The improvement in gross motor performance was accompanied by an improvement in speech motor performance in terms of louder speech and shorter, larger and faster tongue body movements. The tongue body is more agile under levodopa increase, a fact that is not necessarily detectable on the acoustic level but important for speech therapy.Entities:
Keywords: Parkinson’s disease; articulation; levodopa; prosody; speech kinematics; speech production; vowel
Year: 2021 PMID: 34064356 PMCID: PMC8147761 DOI: 10.3390/brainsci11050594
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Patients’ demographic and clinical characteristics. In addition, information about the PD subtype (AR = akinetic-rigid, E = equivalent, TD = tremor-dominant) and levodopa daily dose (LEDD [61]).
| Patient | Gender | Age | Disease Duration (Years) | UPDRS III Med-OFF | UPDRS III Med-ON | Subtype | LEDD |
|---|---|---|---|---|---|---|---|
| (Med-OFF) | |||||||
| PD01 | m | 53 | 4 | 45 | 24 | E | 540 |
| PD02 | m | 54 | 6 | 44 | 27 | AR | 720 |
| PD03 | m | 58 | 2 | 20 | 11 | TD | 826 |
| PD04 | f | 51 | 6 | 41 | 20 | E | 934 |
| PD05 | f | 56 | 6 | 45 | 29 | E | 450 |
| PD06 | f | 70 | 20 | 27 | 14 | E | 1400 |
| PD07 | m | 63 | 10 | 35 | 16 | AR | 1197 |
| PD08 | m | 65 | 3 | 20 | 20 | E | 300 |
| PD09 | m | 60 | 8 | 48 | 19 | AR | 2311 |
| PD10 | m | 56 | 1 | 30 | 16 | E | 300 |
| PD11 | f | 56 | 2 | 16 | 15 | E | 420 |
| PD12 | m | 68 | 12 | 36 | 8 | AR | 1158 |
| PD13 | m | 54 | 5 | 26 | 12 | AR | 1030 |
| PD14 | f | 69 | 13 | 41 | 27 | AR | 1387 |
| PD15 | m | 79 | 2 | 31 | 27 | E | 700 |
| PD16 | m | 69 | 13 | 50 | 22 | AR | 983 |
| mean | - | 61.3 | 7.1 | 34.69 | 19.19 | - | 916 |
| (±sd) | (8) | (5.3) | (10.8) | (6.4) | (517) |
Procedure of the experiment.
| UPDRS Video | med-OFF |
| Speech recordings | |
| 200 mg levodopa intake and break | |
| UPDRS video | med-ON |
| Speech recordings | |
Figure 1Game-like scenario to elicit target words.
Figure 2Target words divided into two sets depending on C1.
Figure 3Articulatory landmarks of a schematized gesture.
Figure 4Coordination of articulatory gestures and acoustic segments within a CV syllable.
Figure 5Presentation of z-transformed values (mean and sd) of acoustic measurements depending on medication condition and prominence condition.
Means and standard deviations for acoustic parameters of interest depending on prominence condition and medication condition.
| Parameter | Condition | Background | Broad | Contrastive |
|---|---|---|---|---|
| Vowel duration (ms) | med-OFF | 120 (30) | 130 (33) | 134 (31) |
| med-ON | 116 (30) | 130 (29) | 136 (29) | |
| Tonal range (st) | med-OFF | 0.58 (1.5) | 2.12 (1.9) | 3.24 (2.2) |
| med-ON | 0.28 (0.9) | 2.26 (2.4) | 3.53 (2.6) | |
| Intensity (dB) | med-OFF | 72 (5) | 74 (5) | 74 (5) |
| med-ON | 76 (6) | 78 (6) | 78 (6) | |
| VAI | med-OFF | 0.94 (0.13) | 0.98 (0.13) | 0.99(0.12) |
| med-ON | 0.92 (0.13) | 0.96 (0.08) | 0.96 (0.08) |
Figure 6Vowel space area per prominence condition. Medication condition is indicated by color: med-OFF (orange) and med-ON (blue).
Means and standard deviations for articulatory parameters of interest depending on prominence condition and medication condition.
| Parameter | Condition | Background | Broad | Contrastive |
|---|---|---|---|---|
| Vocalic gesture duration (ms) | med-OFF | 173 (40) | 183 (46) | 184 (41) |
| med-ON | 164 (40) | 177 (45) | 178 (44) | |
| Displacement (mm) | med-OFF | 7.4 (4.4) | 7.8 (4.6) | 7.9 (4.7) |
| med-ON | 7.6 (5.1) | 8.4 (5.9) | 8.3 (5.4) | |
| Peak velocity (mm/s) | med-OFF | 74 (43) | 77 (42) | 79 (44) |
| med-ON | 81 (50) | 84 (51) | 85 (51) |
Figure 7Presentation of z-transformed values (mean and sd) of articulatory measurements depending on medication condition and prominence condition.
Acoustic–articulatory relations: Coordination patterns (mean and sd) between the vocalic tongue body movement and the acoustic CV syllable. Negative values indicate that the landmark lies before the syllable. Positive values indicate an achievement within the acoustic syllable.
| Coordination Pattern | Condition | Background | Broad | Contrastive |
|---|---|---|---|---|
|
| med-OFF | −22 (18) | −21 (16) | −20 (16) |
| med-ON | −20 (19) | −18 (20) | −16 (16) | |
|
| med-OFF | 64 (11) | 64 (11) | 63 (10) |
| med-ON | 62 (12) | 64 (12) | 64 (12) |
Figure 8Schematized summary of results with respect to vowel articulation.
Figure 9Correlation between vocalic gesture duration and disease duration per focus structure in med-OFF and med-ON conditions.